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Congenital insensitivity to pain is a rare autosomal recessive disorder presenting with a spectrum of 
clinical features caused by mutations in different genes. A 10-year-old girl with congenital insensitivity 
to pain, hyposmia and hypogeusia, and her unaffected twin and parents underwent next generation 
sequencing of SCN9A exons and flanking splice sites. Transcript analysis from whole blood successfully 
assayed the effect of the mutation on the mRNA splicing by PCR amplification on cDNA and Sanger 
sequencing. We identified the novel splicing variant c.1108-2A>G compound with the p.Arg896Gln 
(c.2687G>A) missense mutation previously described in a homozygous patient. The new intronic 
variant was predicted to induce exon 10 skipping. Conversely, SCN9A mRNA assay demonstrated its 
partially deletion with a loss of 46 nucleotides causing a premature stop codon in position p.Gln369 
(NP_002968). Genetic analysis showed that the two variants were biallelic, being the mother and 
brother heterozygous carriers of the missense mutation, and the father heterozygous for the splicing 
mutation. Skin biopsy showed lack of Meissner’s corpuscles, loss of epidermal nociceptors and normal 
autonomic organ innervation. We report a novel splicing mutation and provide clues on its pathogenic 
effect, broadening the spectrum of genotypes and phenotypes associated to congenital insensitivity 
to pain. 
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Congenital insensitivity to pain (CIP) is a rare autosomal recessive syndrome encompassing a 
spectrum of clinical features that include hyposmia or anosmia, mental retardation, fever episodes, 
anhydrosis and other autonomic dysfunctions. Central to the disorder is the inability of affected 
subjects to transmit potentially noxious stimuli throughout the nociceptive pathway. The lack of pain 
perception and, therefore, of its awareness, leads to the accumulation of injuries, bruises, bone 
fractures, and other tissue injuries such as tongue or finger wounds due to self-biting and multiple 
burns, which contribute in reducing life expectancy of affected children. Mutations in different genes 
essential for pain sensing have been described is patients harboring party different 
phenotypes.(Nahorski, et al., 2015)  
The first description of a person who apparently did not feel any pain except headache was published 
in 1932 (Dearborn, 1932). More structured clinical descriptions, including anhydrosis and mental 
retardation, date back to the 50s’ of the 20thcentury,(Schon, et al., 1993) about 50 years before the 
discovery of the first causative mutations in NTRK1, the gene encoding a tyrosine receptor for nerve 
growth factor (Indo, et al., 1996). The syndrome was classified as hereditary sensory and autonomic 
neuropathy (HSAN) type IV or congenital insensitivity to pain and anhydrosis (OMIM256800), and the 
role of NTRK1 was later elucidated(Shaikh, et al., 2017). Mutations in NGFB have been associated with 
childhood or adult onset of insensitivity to pain and classified as HSAN type V (Nahorski, et al., 2015).  
A phenotype most commonly limited to insensitivity to pain and anhydrosis, with invariably normal 
intelligence, has been associated to loss-of-function mutations, principally nonsense, of SCN9A 
encoding the 1.7 sodium channel α subunit (OMIM: 603415).(Cox, et al., 2006) Evidence of the 
genetic and phenotypic heterogeneity of the syndrome, named also channelopathy-associated 
insensitivity to pain (OMIM 243000), came thereafter with the identification of further SCN9A 
mutations.(Bogdanova-Mihaylova, et al., 2015; Cox, et al., 2010; Goldberg, et al., 2007; Kurban, et al., 
2010; Nilsen, et al., 2009; Peddareddygari, et al., 2014; Shorer, et al., 2014; Staud, et al., 2011; 
Wheeler, et al., 2014; Yuan, et al., 2011) In these patients, large neuron-dependent sensory 
modalities, such as touch and proprioception, are unaffected or mildly affected as shown by sural 
nerve biopsy and nerve conduction studies (Ahmad, et al., 2007; Yuan, et al., 2013). Hyposmia or 
anosmia, hypogeusia, bone dysplasia, and variable autonomic dysfunctions can enrich the clinical 
picture (Bartholomew, et al., 2014; Yuan, et al., 2013). More recently, a gain-of-function mutation in 










SCN11A encoding the 1.9 sodium channel α subunit has been found to segregate with the phenotype 
of insensitivity to pain, anosmia, hyperhidrosis, gastrointestinal dysfunction, mild muscular weakness 
and, in some patients, intense pruritus.(Leipold, et al., 2013) 
A small number of inactivating mutations in SCN9A have been published and, among these, truncating 
variants due to nonsense mutations or small ins/del represents the majority. We describe, providing 
evidence of the pathogenic effect and pathological details widening the phenotype, a novel splicing 
mutation biallelic to a known missense mutation in SCN9A found in a young patient with pain 




The proband was a young girl born pre term at the 36th week of pregnancy, twin of a heterozygous 
brother from non-consanguineous parents. She did not show dysmorphic features and had a regular 
motor and intellectual development. At the age of two years, she started biting her tongue, hands and 
feet, and could near her fingers to the flame of a candle without discomfort. The neurological 
examination was normal except for the evidence that she did not retract when stimulated with a 
pricking pin, what was even clearer when punctured for blood tests. Due to her young age, 
quantitative sensory testing (QST), a psychophysical exam requiring the full compliance of the subject, 
could not be performed. Nevertheless, she perceived normally tactile and vibratory stimuli at the 
clinical evaluation. Sensory and motor nerve conduction study showed normal amplitude and velocity 
of upper and lower limb nerves. The dynamic sweat test (DST) was normal indicating an efficient 
sweat production, and dense and homogeneous pattern of activated sweat glands (Fig. 1A). Skin 
biopsy showed that autonomic structures maintained a normal innervation (Fig. 1B) whereas there 
was a complete lack of Meissner’s corpuscles (Fig. 1C, 1D) and a severe reduction of epidermal nerve 
fiber density (1.6/mm) (Fig. 1E, 1F).  
Over the years, the patient attended brilliantly the school and lived a fairly normal life also thanks to 
the familiar support. Even though she learnt how to avoid accidental traumas and self-inflicted 
injuries, she experienced the painless fracture of the elbow bone and several episodes of purulent 
otitis with tympanic membrane perforation. She was re-evaluated at age of eight years, when 
hyposmia and hypogeusia become apparent. DST showed the regular recruitment of sweat glands and 










normal production of sweat after pilocarpine by iontophoresis confirming that sudomotor function 
was not affected. QST showed a normal perception of tactile stimuli tested using Semmes Weinstein 
calibrated monofilaments and normal thresholds for cold and warm innocuous stimuli tested by a 
computer assisted system (Thermal sensory analyzer - TSA 2001 – Medoc) equipped with a 3x3 cm 
Peltier device using the method of limits. She was able to discriminate between mechanical stimuli 
delivered with blunt or sharp probes, whereas pinprick test did not elicit pain. Follow-up skin biopsy 
confirmed the severe reduction of epidermal nerve fibers (0.8/mm) and the lack of Meissner’s 
corpuscles, with retained autonomic dermal annexes innervation. Genetic tests ruled out mutations in 
the exon 17 of NTRK1 gene (cr. 1q23-q31) and in the coding exon of NGFB gene (cr.1p13.1). 
SCN9A mutation screening and mRNA assay 
Patient’s, her twin and parents’ genomic DNA were extracted from peripheral blood sampling with 
Puregene Blood Kit (Qiagen), according to manufacturer instructions. Genetic analysis was performed 
on proband sample by a molecular inversion probe-NGS (MIP-NGS) approach, sequenced on HiSeq 
2500 Illumina platform. Single molecules MIPs were designed to capture the coding and exon-flanking 
intron sequences of nine sodium channel genes expressed in the nociceptive pathway. Relying on the 
association between loss-of-function mutations in the SCN9A gene (HGNC:10597) and the phenotype 
presented, this gene was first investigated. Both NGS results confirmation and the inheritance pattern 
were assessed by Sangers sequencing, using a primer pair covering exon 10 and its flanking splice sites 
(CATGCCTGTCAAATTGAAATA and CCGTTTGCATTTCTACCTCT). Amplicons were purified with 
IllustraExoProStar 1-Step (GE Healthcare) and bi-directionally sequenced using Big Dye Terminator 
v1.1 Cycle Sequencing Kit on a 3130xl Genetic Analyzer System (Applied Biosystems, Thermo-Fisher). 
Splicing consequences were tested on the SCN9Atranscript (NM_002977.3). Total RNA of the proband 
was extracted from peripheral blood collected in a PaxGene Tube, using the PaxGene® RNA extraction 
kit (all by Qiagen), according to manufacturer instructions. Retrotranscription was obtained by using 
SuperScript VILO cDNA Synthesis Kit (Invitrogen), cDNA was amplified in two different PCR reactions, 
using a forward primer hybridizing exon 9 and two different reverse primers, spanning either till exon 
10 or to exon 11 (9F: ACTTTCAGCTGGGCCTTCTT;10R: CAACCACAGCCAGGATCAAG; 11R: 
TGAGAGGCCCATAATTCTGCT). cDNA amplicons were separated on a low-melting agarose gel, 
different sized fragments were cropped out, purified with PureLink™ Quick Gel Extraction Kit 










(Invitrogen™) and then sequenced by Sanger technique as mentioned above. Splicing mutation 
prediction was assessed by Alamut software, provided by Interactive-biosoftware under license. 
 
Results 
After the application of standardized pipeline for the analysis of MIP-NGS data output, two single 
nucleotide variants in SCN9A gene (NM_002977.3) were identified (Fig. 2A): a missense mutation in 
exon 16 leading to a substitution of the arginine residue in position 896 with a glutamine 
(p.Arg896Gln), and a nucleotide substitution affecting the exon 9 splice acceptor site (c.1108-2A>G). 
Inheritance testing demonstrated the biallelic condition. SCN9A gene sequencing on the unaffected 
family members showed the heterozygous missense mutation in the mother and the brother, 
whereas the father harbored the heterozygous splicing mutation. The proband transcript analysis was 
carried out by the amplification of the exonic region interested by the splicing mutation and revealed 
the presence of an unexpected amplicon band, 46bp shorter than the control, and the WT allele 
bands (Fig. 2B). Sanger sequencing of the shorter fragment showed a 46 bp deletion indicating the 
delocalization of intron 9 splice acceptor site 46 nucleotides downstream within the exon 10 (Fig. 2C). 
 
Discussion 
We reported a new SCN9A splicing mutation in a compound heterozygous young patient presenting 
with CIP, hyposmia and hypogeusia. The clinical features resembled those observed in the majority of 
patients previously reported as affected by loss-of-function SCN9A mutations. Indeed, our patient 
showed normal intelligence and autonomic functions, and had no dysmorphisms.  
The missense mutation p.Arg896Gln localizes in the transmembrane region that delimits the channel 
pore in the second domain (S5-S6/DII). It was previously identified in a homozygous CIP patient from 
consanguineous Bedouin parents and reported to have to a loss-of-function effect on the 
protein.(Cox, et al., 2010) This study highlighted the importance of the aminoacid sequence delimiting 
the pore region, which is highly conserved between orthologous and paralogous genes, not only for 
the electrophysiological properties of the channel, but also for its correct folding and surface 
localization. Recently, this variant has been reported in dbSNP (rs1024152367) with a minor allele 
frequency of 8x10-6 (www.ncbi.nlm.nih.gov/projects/SNP).  










The novel intronic variant c.1108-2A>G found in our patient was neither reported in literature nor in 
public databases. It affects the splice acceptor site of intron 9. Several bioinformatics tools (MaxEnt, 
NNSPLICE, HSF, SpliceSiteFinderLike, GeneSplicer, Hum Splicing Finder) predicted a strong effect on 
the splicing mechanism inducing exon 10 skipping. To investigate the effect of the splicing mutation 
on the transcript, we analysed the SCN9A mRNA obtained from patient’s whole blood. The potentially 
mis-spliced region, from exon 9 to exon 11, was amplified by standard PCR. The fragments 
dimensional analysis on agarose gel showed the presence of two bands, one showing the expected 
length and a shorter one that was further characterized by Sanger sequencing. Differently from what 
predicted in silico, the exon 10 was not skipped but only partially deleted. Indeed, the nucleotide 
substitution in c.1108-2 caused the displacement of the canonical acceptor splice site by 46 
nucleotides within the exon 10. The loss of 46 nucleotides at the mRNA level (r.1108_1153del46) 
induced a shift in the reading frame, introducing a stop codon in position p.Gln369 (NP_002968). 
The expression pattern of SCN9A in different cell types is still not fully defined. Interestingly, we have 
found sufficient traces of SCN9A transcript in whole blood sampling to allow a direct study of the 
mutation effect at the mRNA level, making redundant the in vitro model for the splicing mutation 
assay. 
Skin biopsy analysis allowed expanding the features of the phenotype associated with this compound 
mutation. Indeed, we first demonstrated the lack of Meissner’s mechanoreceptors, despite light 
touch sensation was normal as expected (Nahorski, et al., 2015). Moreover, there was a severe 
denervation of the epidermis reflecting the loss of terminal nociceptors and explaining the lack of 
peripheral pain sensation. This finding is common to other inherited forms of CIP. Finally, structure 
and innervation density of cutaneous autonomic organs, including sweat glands, were normal 
differently from what expected in patients harboring mutations in NTRK1, NGFB, and PRDM12 genes 
in whom and anhydrosis is associated with CIP (Nahorski, et al., 2015). 
Albeit overlapping, some phenotypic features might address the molecular diagnosis of CIP patients 
who, however, should be tested for all known genes when using next generation sequencing 
approach. SCN9A inactivating mutations should be searched in patients with anosmia, normal 
intelligence and normal (Ahmad, et al., 2007) or mildly abnormal (Yuan, et al., 2013) large sensory 
nerve fiber function. In patients with normal intelligence showing a pattern of pain insensitivity 
restricted to the limbs rather than diffuse and no anosmia, mutations in PRDM12 should be 










considered.(Zhang, et al., 2016) CIP patients with normal intelligence, hyperhidrosis, gastrointestinal 
dysfunction and mild muscular weakness, without anosmia, neuropathy, or cardiovascular 
dysautonomia could harbor SCN11A mutations (Leipold, et al., 2013). When CIP is associated with 
impaired cognitive development and anhydrosis, the underlying molecular defect could be in the 
NTRK1 gene (Shaikh, et al., 2017).  
We have identified and characterized a new molecular defect of SCN9A in a young patient with CIP, 
hyposmia and hypogeusia that widens the spectrum of Nav1.7 impairments underlying this 
phenotype, and have demonstrated the effect of the mutation on whole blood transcript assay. 
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Figure 1. A shows the normally dense and homogeneous pattern of sweat drop imprints obtained in the 
patients after pilocarpine stimulation by dynamic sweat test. Consistently, B shows the normal pattern of 
sweat gland innervation by postganglionic sudomotor nerves. Confocal micrographs of glabrous (C, D) and 
hairy (E, F) skin biopsy sections from the patient (C, E) and an age-matched healthy subject (D, F). In C, 
note the complete lack of Meissner corpuscles and in E the severe reduction of intraepidermal nerve fiber 
density, compared to D and F, respectively. In green, nerve fibers marked with the pan neuronal marker 
protein-gene-product 9.5; in red, blood vessels and basement membranes marked with collagen IV; in blue, 
endothelia and keratinocytes marked with ULEX Europaeus. Scale bar equals 100 µm.  
 














Figure 2. A. Localization of the two null mutations in Nav1.7 structure. The splicing mutation c1108-2A>G 
on the paternal allele induces the premature truncation from the sixth segment of the first domain (S6-DI). 
The missense mutation on the maternal allele is localized in the pore-delimiting region.  
B. Proband SCN9A genomic sequencing, on the left side, revealed a nucleotide substitution in position 
c.1108-2.  The run on agarose gel shown different bands from the SCN9A transcript amplification: in the 
patient lane (P) there is an unexpected fragment compared to the healthy control (C). Sanger sequencing of 
the two bands, on the right side, revealed the deletion of 46 nucleotides as consequence of the canonical 
splicing site abolition and the new splicing-acceptor site recognition.  
C.  The splicing mutation on the genomic DNA and cDNA led to the deletion of 46 nucleotides on the mature 
transcript. Black arrows indicate the primer pair used for the cDNA amplification and sequencing.  
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